XOLAIR (Genentech, Inc.)
Welcome to the PulseAid listing for the XOLAIR drug offered from Genentech, Inc.. This Anti-IgE [EPC],Decreased IgE Activity [PE],IgE-directed Antibody Interactions [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Genentech, Inc. |
| NON-PROPRIETARY NAME: | omalizumab |
| SUBSTANCE NAME: | OMALIZUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Anti-IgE [EPC],Decreased IgE Activity [PE],IgE-directed Antibody Interactions [MoA] |
| ROUTE: | SUBCUTANEOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2003-06-20 |
| END MARKETING DATE: | 0000-00-00 |
XOLAIR HUMAN PRESCRIPTION DRUG Details:
| Item Description | XOLAIR from Genentech, Inc. |
| LABELER NAME: | Genentech, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 202.5(mg/1.4mL) |
| START MARKETING DATE: | 2003-06-20 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 50242-040_7eafb2a9-969a-41c2-b0f5-113765912803 |
| PRODUCT NDC: | 50242-040 |
| APPLICATION NUMBER: | BLA103976 |
Other OMALIZUMAB Pharmaceutical Manufacturers / Labelers:
